Sydney Lupkin
speaker
1,087 appearances
111 recordings
3 series
first heard Dec 2024
last heard 2d ago
Sydney Lupkin’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 96 in all, peaking in Sep 2026 with 23.
Appearances
But generally, pills are easier to manufacture.
Therefore, they're cheaper to manufacture, which could result in a downstream lower price.
We also know that there have been deals with the Trump administration announced earlier this year to sell the pills to consumers not using their health insurance for $149 a month.
Now, that is not a sticker price, but it could mean that a lower sticker price is coming.
And that could mean better insurance coverage, more access.
Basically, just more people able to get their hands on these if they need them.
Sydney Lupkin, thank you so much for joining us.
Eli Lilly is the company behind blockbuster obesity drug Zepbound.
Now it's working on a next generation medicine.
Eli Lilly's experimental new drug is called Retatrutide.
It's still being studied and hasn't yet been submitted to the Food and Drug Administration for approval, but new study results show that patients taking the highest dose of the drug lost an average of 72 pounds over 68 weeks, according to the company.
Patients in the trial had knee arthritis.
And researchers found that the drug also markedly reduced patients' knee pain.
Side effects for retitrutide included nausea, constipation, and vomiting.
Lilly said the results will be presented at a future medical meeting and published in a peer-reviewed journal.
Sydney Lepkin, NPR News.
We don't want the chaos that is out in the media.
in this courtroom.
Eli Lilly is the company behind blockbuster obesity drug Zepbound.
Now it's working on a next generation medicine.
Showing 761–780 of 1,087 · page 39 of 55
← Previous
Next →